NEW YORK, Feb. 12, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of GW Pharmaceuticals plc (“GW Pharmaceuticals”) (NASDAQ:GWPH) between December 4, 2014 and January 8, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to: http://zlk.9nl.com/gw-pharmaceuticals.
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company lacked effective internal financial controls; (ii) the Company lacked effective controls over completeness and valuation of clinical trial accruals; and (iii) as a result of the foregoing, Defendants’ statements about GW Pharmaceuticals’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
In its 2015 Annual Report, GW Pharmaceuticals disclosed the discovery of a material weakness in its internal control over financial reporting for the year ended September 30, 2015. The Company noted that “management does not have sufficiently precise controls to evaluate the completeness and accuracy of the calculation of clinical trial accruals due to the incorrect allocation of expenditure to clinical studies.” On this news, GW Pharmaceuticals stock fell $3.55, or nearly 6%, to close at $56.31 per share on January 11, 2016.
If you suffered a loss in GW Pharmaceuticals you have until March 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/gw-pharmaceuticals.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 



